Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06516952 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
A Phase 3 study of Prurigo Nodularis, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
- 20
- Study locations
NCT06516952: Recruiting Phase 3 study of Prurigo Nodularis, sponsored by Incyte Corporation.
NCT06516952 is a Phase 3 study of Prurigo Nodularis that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 330 participants, above the 206-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (60% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06516952, a Phase 3 study of Prurigo Nodularis, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Primary Outcome
Defined as proportion of participants achieving a ≥ 4-point improvement \[reduction\] in Itch NRS score from baseline (Itch NRS4) and an IGA CPG-S score of 0 or 1 with a ≥ 2-grade improvement from baseline (IGA-CPG-S-TS).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Povorcitinib
Study Locations (20)
Florida
- Rendon Center the Dermatology and Aesthetic Center - Boca Raton
- Driven Research Llc - Coral Gables
- University of Miami Miller School of Medicine - Miami
- Research Institute of the Southeast, Llc - West Palm Beach
Illinois
- Illinois Dermatology Institute the Chicago Loop - Chicago
- Chicago Cosmetic Surgery and Dermatology - Chicago
- Center For Medical Dermatology and Immunology Research - Chicago
- Northshore University Healthsystem - Skokie
Michigan
- Oakland Hills Dermatology - Auburn Hills
- Hamzavi Dermatology - Fort Gratiot
- Somerset Skin Centre - Troy
Arkansas
- Premier Dermatology Clinical Trials Institute At Northwest Arkansas - Fayetteville
- Burke Pharmaceutical Research - Hot Springs
California
- Dermatology Research Associates - Los Angeles
- Northridge - Northridge
Missouri
- Medisearch Clinical Trials - Saint Joseph
- Washington University School of Medicine - St Louis
Alabama
- Cahaba Dermatology - Birmingham
Arizona
- Banner - University Medicine Multispecialty Services Clinic - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2024-10-10 |
| Est. Completion | 2027-05-03 |
| Phase | Phase 3 |
What NCT06516952 shows while recruiting
NCT06516952 is an interventional study that assigns participants to a tested intervention. The registered 330 participants enrollment target is mid-sized for trials with a published cap, above the 206-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (60% higher).
The record links to 1 condition, with Prurigo Nodularis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06516952 names 20 study sites across 9 states, led by Florida, Illinois, Michigan.
Frequently Asked Questions
What is clinical trial NCT06516952 about?
NCT06516952 is a clinical study titled "A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)". The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
What is the current status of trial NCT06516952?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2024-10-10. Estimated completion is 2027-05-03.
What conditions does trial NCT06516952 study?
This clinical trial studies the following conditions: Prurigo Nodularis.
What interventions are being tested in trial NCT06516952?
The interventions under investigation include: Placebo (DRUG), Povorcitinib (DRUG).
Who is sponsoring clinical trial NCT06516952?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06516952 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prurigo Nodularis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06516952's enrollment target sits among peer trials
330 4th of 14 higher than 10 of 14 other Prurigo Nodularis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prurigo Nodularis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
RECRUITING · Phase 3
-
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
RECRUITING · Phase 3
-
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
ACTIVE NOT RECRUITING · Phase 3
-
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
COMPLETED · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
- NCT03932773 · 330 participants · NA
Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI